Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vemurafenib effect on acenocoumarol pharmacokinetics in BRAF V600-mutant metastatic malignancy
NL-OMON40270Phase 1Not yet recruiting
- Sponsor
- Roche
- Start
- Jul 2013
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of vemurafenib and acenocoumarol in melanoma and Nonhematologic neoplasms, sponsored by Roche. Primary endpoints: R-acenocoumarol AUC0-t, R-acenocoumarol AUC0-inf and 10 more. Planned start Jul 2013; status: not yet recruiting.
02
Drugs
vemurafenibacenocoumarol
03
Conditions
melanomaNonhematologic neoplasms
Beyond the preview
Go deeper on NL-OMON40270.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON40270.